Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Nephrology
Volume 2014, Article ID 308729, 4 pages
Case Report

Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury

1Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Auerbach Street 110, 70179 Stuttgart, Germany
2Department of Pathology, Erlangen University Hospital, Krankenhaus Street 8-10, 91054 Erlangen, Germany

Received 28 March 2014; Accepted 4 August 2014; Published 14 August 2014

Academic Editor: Ichiei Narita

Copyright © 2014 David Callau Monje et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. The HCV infection is a common disease with many chronically infected patients worldwide. So far, the standard therapy of a chronic HCV infection consisted of interferon as single therapy or in combination with ribavirin. After approval of the two protease inhibitors, boceprevir and telaprevir, the standard therapy for patients with genotype 1 changed. In patients with acute kidney injury (AKI) these therapies are not approved and have so far not been evaluated in studies. Case Report. In April 2012, a 58-year-old female was admitted due to a cryoglobulin-positive chronic HCV infection which had been treated with interferon and ribavirin. Currently, the patient was admitted because of severe complications with an acute kidney injury. We treated our patient successfully with a boceprevir based triple therapy. Conclusion. Limited data suggests that a therapy with ribavirin in patients with AKI seems to be safe under close monitoring. Our patient was treated successfully with a protease inhibitor based triple therapy. Nevertheless, it is necessary to plan an interventional study to evaluate the exact risk-benefit profile of triple therapy regimens in patients with AKI and hepatitis C.